ClinicalTrials.gg
Enrolling by invitationNCT05570708TherPsySEUpdated Apr 14, 2025

The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training

An interventional study of MDMA, LSD, psilocybin in Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD, sponsored by Felix Mueller. Enrolling by invitation at 1 site in Switzerland. Open to participants aged 27 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-14.

Sponsored by Felix Mueller · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
27 Years and older
Sex
All
01

Study summary

The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced altered states of consciousness for physicians or psychotherapists in the context of a training course for substance-assisted therapy. Specifically, the study aims to assess changes in therapeutic attitude and other factors important in interactions between patients and therapists (such as empathy and cognitive flexibility).

02

Conditions studied

  • Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD
03

In context

Lead sponsor

Felix Mueller is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
27 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation in the SÄPT therapist training (medical doctors and psychologists)
  • Age 27 years or older
  • Sufficient understanding of the German language
  • Understanding of procedures and risks associated with the study
  • Willing to adhere to the protocol and signing of the consent form
  • Willing not to operate heavy machinery (including driving cars) within 24 hours after substance administration
  • Woman of are required to use effective, established , such as oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository at least one month before and after each study substance intervention, and are willing to take a urine pregnancy test at the medical screening and before every study substance intervention.
  • Men are required to use contraceptive methods in the month after each study substance intervention and are required to inform their partner(s) about their study participation.

Exclusion criteria

Exclusion Criteria:

  • Previous significant adverse response to a hallucinogenic drug
  • Significant medical condition rendering volunteers unsuitable for participation (such as impaired kidney or liver function, or heart disease incl. uncontrolled hypertension or hypotension)
  • Strong underweight (\<45kg)
  • Current major psychiatric disorder (including personality disorder, including suicidality) and / or previous psychotic or bipolar disorder.
  • Psychotic disorder or bipolar disorder in first-degree relatives
  • Use of medication that may interfere with the effects of the study medication. Patients must be willing to discontinue medications in cases where drug-related interactions are possible (the phase will be at least 5 times the particular drug's half-life [typically 3-7 days] prior to the respective study session). Discontinuation of medication must be judged to be acceptable by the responsible investigator.
  • Women are excluded from substance intervention during pregnancy or breastfeeding.
  • nParticipation in another clinical trial (currently or within the last 30 days)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Personal experience of substance-assisted therapy using psilocybin, MDMA, and LSD

    Drug: MDMA, LSD, psilocybin

Interventions

06

What researchers measure

Primary outcomes

  1. TASC-2 scale

    The primary endpoint is changes on the TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)

    Time frame: Three weeks after last PE

Secondary outcomes

  1. semi-structured interview

    A semi-structured interview will be used to explore the range of effects and systematically collect and record subjective effects of the personal experience

    Time frame: Five months after last PE

  2. TASC-2 scale

    TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)

    Time frame: Three weeks after each PE and six months after last PE

  3. SOCS-S

    Compassion with self

    Time frame: Three weeks after each PE and six months after last PE

  4. SPCS-O

    Compassion with others

    Time frame: Three weeks after each PE and six months after last PE

  5. SPF/IRI

    Empathy questionnaire

    Time frame: Three weeks after each PE and six months after last PE

  6. 5D-ASC

    5 dimensions of altered states of consciousness questionnaire

    Time frame: Directly after each PE

  7. CEQ

    Challenging experience questionnaire

    Time frame: Directly after each PE

  8. APEQ

    Acceptance /avoidance-promoting experiences questionnaire

    Time frame: Directly after each PE

  9. PIQ

    Psychological insights questionnaire

    Time frame: Directly after each PE

  10. CSOWD

    Connectedness scale

    Time frame: Directly after each PE

  11. EBI

    Emotional breakthrough inventory

    Time frame: Directly after each PE

  12. BFW/E

    Berner Subjective Well-Being questionnaire

    Time frame: Three weeks after each PE and six months after last PE

  13. PEQ

    Persisting effects questionnaire

    Time frame: Three weeks after each PE and six months after last PE

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Jun 2029, 79 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Oct 7, 2022
StartActual
Oct 25, 2022
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Apr 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05570708
Lead sponsor
Felix Mueller
Collaborators
Swiss Medical Society for Psycholytic Therapy
Responsible party
Felix Mueller (Sponsor-Investigator PD Dr. med. Felix Müller MD, University Hospital, Basel, Switzerland) — Sponsor-investigator
First posted
Oct 7, 2022
Start date
Oct 25, 2022
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Apr 14, 2025

Study contacts

Felix Müller, MD
principal investigator · University of Basel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: N-Methyl-3,4-methylenedioxyamphetamine · Lysergic Acid Diethylamide · Psilocybin

Start the discussion